Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro ...

Zepbound vs. Wegovy For Weight Loss: What’s The Difference?

If you’re weighing the option of Wegovy versus Zepbound for weight loss, here’s how the two medications compare in terms of ...
CNBC

Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply

Eli Lilly released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to increase access for patients without insurance coverage for the highly popular ...
BioSpace

Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or ...
WIBC

Eli Lilly’s Zepbound Vials are Increasing Health Accessibility in Indiana

Discover how Eli Lilly is increasing medical weight loss access in Indiana through Zepbound vials. Learn how this Indy innovation supports long-term health. By combining lower pricing, direct-to ...

Zepbound vs. Mounjaro For Weight Loss: What’s The Difference?

Mounjaro and Zepbound are two brand-name glucagon-like peptide-1 (GLP-1) medications manufactured by Eli Lilly. Although they ...

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of ...